{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:06:53Z","timestamp":1777547213953,"version":"3.51.4"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T00:00:00Z","timestamp":1466035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0157098","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T15:39:08Z","timestamp":1466091548000},"page":"e0157098","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Drug Pricing Evolution in Hepatitis C"],"prefix":"10.1371","volume":"11","author":[{"given":"Nathalie","family":"Vernaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Girardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urs","family":"Br\u00fcgger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Riguzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Negro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,6,16]]},"reference":[{"issue":"5","key":"ref1","first-page":"e0126984","article-title":"Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C","volume":"10","author":"AM Pfeil","year":"2015"},{"issue":"12","key":"ref2","first-page":"991","article-title":"The way forward in HCV treatment\u2014finding the right path","volume":"6","author":"MP Manns","year":"2007"},{"issue":"40","key":"ref3","first-page":"6703","article-title":"Hepatitis C, stigma and cure","volume":"19","author":"RT Marinho","year":"2013"},{"issue":"2","key":"ref4","first-page":"395","article-title":"A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C","volume":"34","author":"KL Lindsay","year":"2001"},{"issue":"9286","key":"ref5","first-page":"958","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"MP Manns","year":"2001"},{"issue":"25","key":"ref6","first-page":"2405","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"IM Jacobson","year":"2011"},{"issue":"13","key":"ref7","first-page":"1195","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011"},{"issue":"1","key":"ref8","first-page":"31","article-title":"Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2\/3","volume":"59","author":"MO Silva","year":"2013"},{"issue":"21","key":"ref9","first-page":"1983","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"P Ferenci","year":"2014"},{"issue":"20","key":"ref10","first-page":"1879","article-title":"Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis","volume":"370","author":"KV Kowdley","year":"2014"},{"issue":"20","key":"ref11","first-page":"1878","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"E Lawitz","year":"2013"},{"issue":"17","key":"ref12","first-page":"1594","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"JJ Feld","year":"2014"},{"issue":"9941","key":"ref13","first-page":"403","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"IM Jacobson","year":"2014"},{"issue":"9941","key":"ref14","first-page":"414","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"M Manns","year":"2014"},{"issue":"3","key":"ref15","first-page":"211","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"MS Sulkowski","year":"2014"},{"issue":"2","key":"ref16","first-page":"e73","article-title":"Hepatitis C drug affordability","volume":"3","author":"M Kamal-Yanni","year":"2015"},{"key":"ref17","first-page":"h3222","article-title":"Thousands of patients in England to get new hepatitis C drugs","volume":"350","author":"Z Kmietowicz","year":"2015"},{"key":"ref18","first-page":"676","article-title":"Aff onso de Ara\u00fajo E, Hamid S. Disparity in market prices for hepatitis C virus direct-acting drugs","volume":"3","author":"CJ Andrieux-Meyer I","year":"2015"},{"issue":"2","key":"ref19","first-page":"151","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"JA DiMasi","year":"2003"},{"issue":"4","key":"ref20","first-page":"539","article-title":"Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs","volume":"1","author":"S Mailankody","year":"2015"},{"issue":"12","key":"ref21","first-page":"959","article-title":"Lessons from 60 years of pharmaceutical innovation","volume":"8","author":"B Munos","year":"2009"},{"key":"ref22","article-title":"Pharmaceutical pricing and reimbursement policies in Switzerland","volume":"27","author":"V Paris","year":"2007"},{"issue":"6","key":"ref23","first-page":"e0125214","article-title":"Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland","volume":"10","author":"B Mullhaupt","year":"2015"},{"key":"ref24","article-title":"Twenty-Five Years of Progress against Hepatitis C: setbacks and Stepping Stones","year":"2014"},{"key":"ref25","first-page":"1610","article-title":"Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C","volume":"484","author":"FG Girardin","year":"2015"},{"issue":"18","key":"ref26","first-page":"2793","article-title":"Sustained virological response: a milestone in the treatment of chronic hepatitis C","volume":"19","author":"F Morisco","year":"2013"},{"key":"ref27","article-title":"Ispor Global Health Care Systems Road Map: Switzerland","author":"KR M\u00fcller","year":"2011"},{"key":"ref28","first-page":"f2686","article-title":"Correlation versus linear regression","volume":"346","author":"P Sedgwick","year":"2013"},{"key":"ref29","unstructured":"FDA. Roferon label."},{"key":"ref30","unstructured":"Swissmedic. Rebetol label."},{"key":"ref31"},{"issue":"3","key":"ref32","first-page":"744","article-title":"Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C","volume":"146","author":"M Buti","year":"2014"},{"issue":"20","key":"ref33","first-page":"1889","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014"},{"issue":"6","key":"ref34","first-page":"e1001460","article-title":"Patented drug extension strategies on healthcare spending: a cost-evaluation analysis","volume":"10","author":"N Vernaz","year":"2013"},{"issue":"12","key":"ref35","first-page":"2329","article-title":"Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement","volume":"30","author":"PJ Neumann","year":"2011"},{"key":"ref36","first-page":"h5989","article-title":"US Senate committee launches investigation into drug pricing","volume":"351","author":"M McCarthy","year":"2015"},{"issue":"4","key":"ref37","first-page":"1174","article-title":"Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus","volume":"61","author":"N van de Ven","year":"2015"},{"issue":"4","key":"ref38","first-page":"1187","article-title":"Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response","volume":"60","author":"K Bichoupan","year":"2014"},{"issue":"2","key":"ref39","first-page":"217","article-title":"Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naive patients with genotype 1 HCV infection in Italy","volume":"40","author":"A Messori","year":"2014"},{"issue":"6","key":"ref40","first-page":"397","article-title":"Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States","volume":"162","author":"J Chhatwal","year":"2015"},{"issue":"6","key":"ref41","first-page":"407","article-title":"Cost-effectiveness of novel regimens for the treatment of hepatitis C virus","volume":"162","author":"M Najafzadeh","year":"2015"},{"issue":"4","key":"ref42","first-page":"341","article-title":"Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?","volume":"16","author":"K van de Vooren","year":"2015"},{"issue":"11","key":"ref43","first-page":"1824","article-title":"Hepatitis C virus treatment in the real world: optimising treatment and access to therapies","volume":"64","author":"F Zoulim","year":"2015"},{"issue":"19","key":"ref44","first-page":"1797","article-title":"New Math on Drug Cost-Effectiveness","volume":"373","author":"PB Bach","year":"2015"},{"key":"ref45","first-page":"h2055","article-title":"New drug for hepatitis C contributes to 13% rise in spending on prescription drugs in US","volume":"350","author":"M McCarthy","year":"2015"},{"issue":"1","key":"ref46","first-page":"33","article-title":"A critical systematic review of budget impact analyses on drugs in the EU countries","volume":"12","author":"K van de Vooren","year":"2014"},{"key":"ref47","first-page":"h3363","article-title":"Reducing the price of new hepatitis C drugs in the Tuscany region of Italy","volume":"350","author":"MR Brunetto","year":"2015"},{"key":"ref48","unstructured":"Novartis to test new pricing model with heart failure drug. Reuters. 30 June 2015. [cited: April 24 2016]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/reuters.com\/article\/us-novartis-heart-idUSKCN0PA1N720150630\" xlink:type=\"simple\">http:\/\/reuters.com\/article\/us-novartis-heart-idUSKCN0PA1N720150630<\/ext-link>."},{"key":"ref49","article-title":"Emanuel: The Solution to Drug Prices","author":"J Ezekiel","year":"2015"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0157098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T23:00:58Z","timestamp":1540335658000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0157098"}},"subtitle":[],"editor":[{"given":"Wenzhe","family":"Ho","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,6,16]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0157098","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,16]]}}}